defi trial: nirogacestat vs placebo for patients with progressing desmoid tumors
Published 1 year ago • 184 plays • Length 1:52Download video MP4
Download video MP3
Similar videos
-
1:36
defi: nirogacestat demonstrates improved pfs and orr in progressing desmoid tumors
-
2:30
#esmo22 highlights on first-line atezolizumab in nsclc not eligible for platinum: the ipsos study
-
0:45
nirogacestat emerges as a treatment for desmoid tumor: 2022 esmo florida
-
2:46
#esmo22 highlights on neoadjuvant ici in locally advanced dmmr colon cancer: the niche-2 study
-
3:35
#esmo22 highlights on actionable inflammatory axis for air pollution induced nsclc
-
3:35
#esmo22 highlights on the efficacy and safety of fruquintinib in refractory mcrc: the fresco-2 study
-
2:02
nirogacestat being evaluated for desmoid tumors in adults and children
-
59:05
addressing key questions about the latest diagnostic and therapeutic advances in desmoid tumors
-
6:52
testicular cancer highlights from esmo 2022
-
2:22
treatment options for desmoid tumors, including nirogacestat in children
-
3:11
highlights from esmo sarcoma & gist 2022
-
33:28
esmo 2022: highlights, commentary and analysis
-
1:00
esmo 2022 highlights
-
0:56
highlights from esmo wcgic 2022
-
1:20:12
spaen knowledge spot 2022: medical & other highlights in desmoid tumors 2021
-
0:44
highlights in skin cancer at esmo 2022
-
0:55
esmo 2022 highlights
-
1:31
esmo oncologypro - intro by prof. a. matikas